Pharmaceuticals & Healthcare Bangkok Client Alert June 2015 www.bakermckenzie.com Bangkok 5th Floor and 21st-25th Floors 990 Abdulrahim Place Rama IV Road, Silom, Bangrak Bangkok 10500 Thailand © 2015 Baker & McKenzie. All rights reserved. Baker & McKenzie International is a Swiss Verein with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a “partner” means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an “office” means an office of any such law firm. For further information please contact Peerapan Tungsuwan +66 2636 2000 ext. 4334 email@example.com Yuthana Sivaraks +66 2636 2000 ext. 4902 firstname.lastname@example.org Jantapa Erjongmanee +66 2636 2000 ext. 4023 email@example.com The Code of Conduct for Drug Sales Promotion in Thailand – MOU Signed Following the Notification on the Code of Practices for Procurement and Sales of Drugs and Medical Supplies (the "Notification") issued by the Ministry of Public Health last year, a Memorandum of Understanding on the Code of Conduct for Sales Promotion in Thailand (the "MOU") has been signed to establish standard practices for drug sales promotion. Although the Notification is legally binding for government agencies, private entities are not legally required to abide by its requirements. On 25 March 2015, a Memorandum of Understanding on the Code of Conduct for Sales Promotion in Thailand (the "MOU"), which provides similar criteria to those under the Notification, was signed by relevant stakeholders, including government authorities, professional councils, educational institutes, and private entities in the pharmaceutical industry. The main purpose of the MOU is to establish standard practices for drug sales promotion across various stakeholders. Under the MOU, significant issues include: sponsorship criteria for drug prescribers regarding participation in meetings and seminars and the conduct of research; restrictions prohibiting drug companies or representatives from providing benefits to drug prescribers with the intention of encouraging the purchase of drugs; and obligations for drug companies to provide correct and complete information based on reliable scientific evidence substantiating drugs sales promotion and scientific meetings, without persuading the use of their products. Currently, the criteria under the MOU are being reviewed for its final version, which is expected to be implemented within three months after the signing date.